redeem code 80jili

redeem code 80jili ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 Investors@transmedics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/transmedics-appoints-gerardo-hernandez-as-chief-financial-officer-and-provides-updated-2024-financial-outlook-302320060.html SOURCE TransMedics Group, Inc.President-elect Donald Trump has selected Jared Isaacman, entrepreneur, pilot, and all-around space enthusiast, as the next NASA administrator, marking a major shift in the space agency’s leadership. Trump made the announcement through a post on Truth Social, writing that Isaacman would “drive NASA’s mission of discovery and inspiration, paving the way for groundbreaking achievements in Space science, technology, and exploration.” NASA’s last two appointed administrators have been former politicians, so putting the billionaire astronaut at the helm is rather unconventional for the space agency and a possible indication of the private industry playing a much larger role in the national space program. Fresh off of his first spacewalk, Isaacman stated that he was honored to receive the nomination. “Having been fortunate to see our amazing planet from space, I am passionate about America leading the most incredible adventure in human history,” Isaacman wrote on X. Aside from being the founder and chief executive of payment services company Shift4, the billionaire was able to translate his personal passion for space into reality by commanding two private astronaut missions. Isaacman’s first stint in space, Inspiration4, launched in September 2021 with the first all-civilian crew to reach orbit. Earlier in September, Isaacman led a four-person crew on board a Dragon spacecraft for the Polaris Dawn mission, which reached higher altitudes than any other SpaceX crew capsule. The private spaceflight also saw two crew members hop out of the capsule, performing the first-ever commercial spacewalk and testing SpaceX-designed spacesuits in the vacuum of space. As far as commercial trips to space go, Polaris Dawn set the bar high and took on much more challenging tasks than the regular suborbital flights. “On my last mission to space, my crew and I traveled farther from Earth than anyone in over half a century,” Isaacman wrote on X. “I can confidently say this second space age has only just begun.” If we’re to read anything into this, it’s that this “second space” age is likely to see NASA outsourcing heavily to private companies, continuing what it already an ongoing trend. With a second Trump term looming, there has been speculation that the president-elect may seek to cancel NASA’s Space Launch System (SLS) rocket, which is poised to launch astronauts to the Moon as part of the space agency’s Artemis program. NASA’s massive Moon rocket is marred by delays and cost overruns , and may end up costing six times more than its original value. As a result, the space agency has been struggling with its planned return to the Moon, trying to manage a tight budget while sustaining its ambitious timeline to land humans on Mars. NASA’s 2024 budget was $24.875 billion, about half a billion less than what the space agency received in 2023 and some $2.31 billion short of what it was hoping to spend on its various programs this year. The agency needs more funding for its science endeavors, while the private industry is looking to make money from space. With Isaacman leading NASA, there might be more focus on profiting from the cosmos. “Space holds unparalleled potential for breakthroughs in manufacturing, biotechnology, mining, and perhaps even pathways to new sources of energy,” Isaacman wrote. “There will inevitably be a thriving space economy—one that will create opportunities for countless people to live and work in space.” Isaacman’s close association with SpaceX founder and CEO Elon Musk is also worrying (Isaacman’s missions rely on SpaceX’s Falcon 9 rockets and Crew Dragon capsule). Musk is already a close ally to Trump, and with Isaacman at NASA, the SpaceX billionaire may have an unfair advantage to securing more contracts from the space agency, leading to a full-on monopoly of the industry. Of course, the U.S. Senate still needs to approve Trump’s nomination of Isaacman as the space agency’s administrator. That’s not to say that Isaacman wouldn’t bring a much-needed fresh approach to NASA, with the space agency being weighed down by bureaucracy at times and not taking as many risks as the private industry. For better or worse, Isaaman’s appointment will mark a new era for NASA and spaceflight as a whole.

– As previously reported , a huge matchup was being advertised locally in the Chicago area during last Monday’s WWE Raw for tomorrow’s WWE Live Holiday Tour event in Chicago at the Allstate Arena. That matchup has now been confirmed by WWE World Heavyweight Champion, Gunther. Per Gunther via his social media , he will defend his title tomorrow night against former WWE Champion CM Punk in a Steel Cage Match. This will be the first time Gunther faces CM Punk. Punk has been in action during the Holiday Tour this week, facing Ludwig Kaiser. Meanwhile, Gunther defeated Damian Priest in Steel Cage bouts the previous two nights. This will be the first time Punk wrestles for a WWE title since making his return to the promotion last year. Tomorrow’s non-televised live event is being held at the Allstate Arena in Punk’s hometown of Chicago. This is the same arena where Punk defeated John Cena to win the WWE Championship at WWE Money in the Bank 2011. Tomorrow in Chicago pic.twitter.com/K5bD1oBVdv — GUNTHER (@Gunther_AUT) December 28, 2024MONTREAL — Second Cup Canada is cutting ties with a franchisee operating at Montreal’s Jewish General Hospital who was allegedly filmed making hateful and antisemitic comments during a protest in the city last week. Second Cup Canada announced Saturday it was cutting ties with a franchisee for “making hateful remarks and gestures,” and adding in a statement the actions breach the franchise agreement as well as inclusion and community values ​​held by the chain. Peter Mammas, CEO of Montreal-based Foodtastic, which owns Second Cup Canada, said in an interview on Sunday that he was at the movies when his phone started pinging non-stop. He saw the videos and the company’s operations staff spoke to employees that knew the woman, and they confirmed it was indeed the franchisee. Video shot during a pro-Palestinian demonstration outside of Concordia University’s downtown Montreal campus Thursday shows a woman walking around, masked, saying the “final solution is coming your way” — wording used to describe a Nazi plan to eliminate Jews in Europe during the Second World War. Another video also shows what appears to be the same woman, unmasked, making a Nazi salute while walking away. “We’re all for free speech and respectful conversations, but this wasn’t that,” Mammas said. “This was hate speech, and it was something that we thought could incite violence and we’re completely against that, so we sat down with our team and decided to revoke the franchise agreement.” Attempts to reach the franchisee were unsuccessful on Sunday. “Second Cup has zero tolerance for hate speech,” the coffee chain said in a statement on X. “In co-ordination with the hospital, we’ve shut down the franchisee’s café and are terminating their franchise agreement.” Mammas said lawyers for the franchisee and Second Cup were expected to meet on Monday. The regional health agency serving West-Central Montreal, which includes the Jewish General Hospital, said it was made aware of the video “containing antisemitic and hateful messaging.” The video is related to a franchisee of Second Cup, one of the private tenants operating within the (Jewish General), Carl Thériault, a spokesman, said in a statement on Sunday. “We fully support Second Cup’s decision to take swift and decisive action in this matter by shutting down the franchisee’s cafés and terminating their lease agreement.” The hospital has two locations operated by the same franchisee and both were shuttered on Saturday by the owners of the chain. The health agency “is committed to fostering a culture of inclusion and stands firmly against antisemitism and any other form of discrimination or hate speech,” Thériault said. “We have franchisees who are Muslim, we have franchisees who are Jewish, we have franchisees that are Greek, French, we have employees from all different nations,” Mammas said. “So we definitely have no issue with that and we don’t take any political side, but ... hate speech ... you know we can’t accept that.”

Provident Bancorp, Inc. Adopts Stock Repurchase Program

No. 11 Tennessee crushes UTEP to enhance CFP chances

NoneHewlett Packard Enterprise Co. stock rises Monday, still underperforms marketNuggets forward Vlatko Cancar underwent arthroscopic surgery in his left knee and will be reevaluated in eight weeks, the team announced Wednesday. Cancar, 27, in his left knee. He returned from the injury this summer, playing for the Slovenian national team and then . Cancar was in Denver’s rotation as a backup center, filling in while Nikola Jokic was away from the team, when he . Cancar immediately struggled to put weight on his left leg and asked for a substitution. At the time, the injury was designated as a sprained knee. , Cancar began to seek medical opinions on the best path forward, according to coach Michael Malone. Arthroscopic surgery is generally considered a less invasive form of procedure, one that doesn’t necessarily have to be season-ending for professional athletes.

Elevai Labs announces withdrawal of offer to exchangeWASHINGTON D.C., DC — President-elect Donald Trump announced Wednesday that he intends to nominate cryptocurrency advocate Paul Atkins to chair the Securities and Exchange Commission. Trump said Atkins, the CEO of Patomak Partners and a former SEC commissioner, was a “proven leader for common sense regulations.” In the years since leaving the SEC, Atkins has made the case against too much market regulation. “He believes in the promise of robust, innovative capital markets that are responsive to the needs of Investors, & that provide capital to make our Economy the best in the World. He also recognizes that digital assets & other innovations are crucial to Making America Greater than Ever Before,” Trump wrote on Truth Social. The commission oversees U.S. securities markets and investments and is currently led by Gary Gensler, who has been leading the U.S. government’s crackdown on the crypto industry. Gensler, who was nominated by President Joe Biden, announced last month that he would be stepping down from his post on the day that Trump is inaugurated — Jan. 20, 2025. Trump, once a crypto skeptic, had pledged to make the U.S. “the crypto capital of the planet” and create a “strategic reserve” of bitcoin. Money has poured into crypto assets since he won . Bitcoin, the largest cryptocurrency, is now above $95,000. And shares in crypto platform Coinbase have surged more than 70% since the election. Paul Grewal, chief legal officer of Coinbase, congratulated Atkins in a post on X. “We appreciate his commitment to balance in regulating U.S. securities markets and look forward to his fresh leadership at (the SEC),” Grewal wrote. “It’s sorely needed and cannot come a day too soon.” Atkins began his career as a lawyer and has a long history working in the financial markets sector, both in government and private practice. In the 1990s, he worked on the staffs of two former SEC chairmen, Richard C. Breeden and Arthur Levitt. His work as an SEC commissioner started in 2002, a time when the fallout from corporate scandals at Enron and WorldCom had turned up the heat on Wall Street and its government regulators. Atkins was widely considered the most conservative member of the SEC during his tenure at the agency and known to have a strong free-market bent. As a commissioner, he called for greater transparency in and analysis of the costs and benefits of new SEC rules. He also emphasized investor education and increased enforcement efforts against those who steal from investors over the internet, manipulate markets, engage in Ponzi schemes and other types of fraud. At the same time, Atkins objected to stiff penalties imposed on companies accused of fraudulent conduct, contending that they did not deter crime. He caused a stir in the summer of 2006 when he said the practice of granting stock options to executives before the disclosure of news that was certain to increase the share price did not constitute insider trading. U.S. Rep. Patrick McHenry, a North Carolina Republican and chairman of the House Financial Services Committee, said Atkins has the experience needed to “restore faith in the SEC.” “I’m confident his leadership will lead to clarity for the digital asset ecosystem and ensure U.S. capital markets remain the envy of the world,” McHenry posted on X. Atkins already has some experience working for Trump. During Trump's first term, Atkins was a member of the President’s Strategic and Policy Forum , an advisory group of more than a dozen CEOs and business leaders who offered input on how to create jobs and speed economic growth. In 2017, Atkins joined the Token Alliance, a cryptocurrency advocacy organization. Crypto industry players welcomed Trump’s victory in the hopes that he would push through legislative and regulatory changes that they’ve long lobbied for. Trump himself has launched World Liberty Financial, a new venture with family members to trade cryptocurrencies. ___ AP Aerospace Writer Marcia Dunn in Cape Canaveral, Fla., Josh Boak in Washington and Rob Gillies in Toronto contributed to this report.